(Q52654892)
English
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK.
scientific article published on 14 March 2018
Statements
A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK (English)
Emma Dean
Jan H M Schellens
Matthew G Krebs
Begona Jimenez
Emilie van Brummelen
Chris Bailey
Ed Casson
Diana Cripps
Marie Cullberg
Stephen Evans
Andrew Foxley
Paul Rugman
Nigel Taylor
Guy Turner
James Yates
14 March 2018
1 reference